A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-520730-28-00

Acronym

61186372NSC2012

Enrollment

118

Registered

2025-11-27

Start date

2025-12-08

Completion date

Unknown

Last updated

2025-12-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Brief summary

PFS according to RECIST v1.1 by investigator assessment

Interventions

DRUGJNJ-73841937

DRUGJNJ-61186372

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
PFS according to RECIST v1.1 by investigator assessment	—

Countries

Belgium, Finland, France, Germany, Greece, Italy, Poland, Portugal, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026